Cardiovascular Morbidity and Mortality in Patients with Diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial against Atenolol. - LIFE Diabetic Substudy

Description:

Is angiotensin II receptor blockade (losartan) better than beta-blockers (atenolol) for reducing cardiovascular morbidity and mortality in hypertensive diabetics?